Skip to main
  1. Stocks
  2. Ascendis Pharma
  3. Forecast
ASND

Ascendis Pharma (ASND) Stock Forecast & Price Target

Ascendis Pharma (ASND) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 56%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Ascendis Pharma is supported by a diversified TransCon pipeline with three marketed products that are already showing strong commercial traction, as Q3 revenue of €370M was in line overall while Yorvipath reached €291M, Yuviwel doubled sequentially to €16M, and Skytrofa rose to €59M. The company’s outlook is strengthened by management’s reiterated ≥€5B revenue ambition in 2030 and ≥€10B in 2035, supported by continued U.S. and ex-U.S. expansion, label extensions across age groups and indications, and new combination studies that broaden the addressable market. Fundamentally, the business is also becoming more profitable, with operating cash flow guided to at least €600M in 2026, healthy margins, and buybacks reinforcing the case for accelerating EPS and free cash flow growth.

Bears say

Ascendis Pharma is viewed cautiously because negative readouts from the ongoing later-stage trials for TransCon PTH and TransCon CNP could undermine both regulatory confidence and commercial potential, while any platform-wide safety signal could damage the entire TransCon pipeline. The company has just reached operating profitability, but that milestone may prove fragile if Skytrofa faces intense competition in the large growth hormone market or if Yorvipath adoption is weaker than expected, leading to lower sales and renewed financing needs. Additional downside stems from execution risk, regulatory uncertainty, intellectual property challenges, and long-term pricing pressure, with the downside scenario implying unsuccessful expansion of Skytrofa and TransCon CNP would also erode platform value.

Ascendis Pharma (ASND) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 56% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ascendis Pharma and is not a guaranteed prediction by Public.com or investment advice.

Ascendis Pharma (ASND) Analyst Forecast & Price Prediction

Get the latest Ascendis Pharma (ASND) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ascendis Pharma (ASND)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ascendis Pharma (ASND) Forecast

Analysts have given Ascendis Pharma (ASND) a Buy based on their latest research and market trends.

According to 18 analysts, Ascendis Pharma (ASND) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $317.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $317.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ascendis Pharma (ASND)


Ascendis Pharma (ASND) Analyst Forecast & Price Prediction

Get the latest Ascendis Pharma (ASND) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Ascendis Pharma (ASND)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ASND stock data and trends